Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery

Episode Summary

Executive Summary: Abbas Kazemi traces Nimbus Therapeutics’ evolution from a lean, computation-driven drug discovery shop into a company that repeatedly validates its model through disciplined target selection, capital efficiency, and partnerships. He also shares his immigrant family story, how it shaped his values, and why Nimbus prioritizes people, patient impact, and fast failure over organizational growth for its own sake.

Main Topics: Immigrant family background and worldview (Priority: 5/5): Kazemi describes being born in Saudi Arabia to South Asian immigrant parents, moving across countries, and learning adaptability, humility, and the value of opportunity in America. From curiosity to science to business (Priority: 5/5): He explains his non-linear education path through UT Austin and Harvard, his realization that he was better suited to big-picture thinking than bench science, and his move into biotech business development. Nimbus founding thesis and operating model (Priority: 5/5): Kazemi outlines Nimbus’ original 2009 thesis: small molecules can hit hard targets using structural biology and computation; a virtual, CRO-enabled model can stay lean; and an LLC hub-and-spoke structure can recycle capital efficiently. ACC/NASH validation and Gilead transaction (Priority: 5/5): Nimbus’ ACC program produced unexpected biology in NASH, leading to a successful phase 1b, multiple bidders, and a $1.2B deal with Gilead that validated the company’s platform and business model. TIC2 program, Bristol dispute, and Takeda deal (Priority: 5/5): He recounts Nimbus’ selective TIK2 work, the Celgene/Bristol complications, the lawsuit to regain control, and the eventual $4B upfront Takeda deal that now appears on track to yield a blockbuster psoriasis drug. Culture, talent, and decision discipline (Priority: 5/5): Kazemi emphasizes that Nimbus’ real platform is its people, a culture of empowerment and patient-first values, and the willingness to kill weak programs quickly rather than cling to them. CEO transition and future direction (Priority: 4/5): As new CEO, he wants Nimbus to become a compounding engine with more frequent clinical assets, greater informed risk-taking, and continued strength in computational chemistry and medicinal chemistry.

Key Arguments: Nimbus succeeds because it combines advanced technology with exceptional people; neither is sufficient alone. A lean biotech can repeatedly create value if it stays focused on target selection, capital discipline, and early de-risking. Computational and structural biology are most powerful when used to design molecules intentionally rather than screen broadly and hope for success. The company’s use of CROs and a virtual model allows it to remain nimble without building expensive internal infrastructure. The ACC program proved Nimbus could discover and monetize assets, but the NASH biology also showed the need to partner at the right stage. The TIC2 experience demonstrated that Nimbus can compete with large pharma, defend its assets, and still optimize for patient impact rather than only financial return. Nimbus’ culture rewards internal scientific ownership, fast attrition of weak programs, and celebration of INDs and program shutdowns alike. Kazemi believes the next phase is not a larger company, but a more productive one: more shots on goal, faster target onboarding, and better-informed risk taking.

Data Points: Nimbus age: 17 years - Kazemi says the company is entering its 17th year and still refining its model. Team size: ~70-80 people - Luke describes Nimbus as staying right-sized and lean. Nimbus employees at early success point: 35-40 people - Kazemi says Nimbus reached its first major Gilead transaction with a small team. Equity financing raised: Over $630 million - Kazemi has helped raise this amount since joining Nimbus. Transactions led: Over $8 billion - Total corporate and business development transactions he has helped lead. Takeda upfront payment: $4 billion - Sale of the TIC2 asset to Takeda in late 2022. Takeda milestones: Another $2 billion - Additional payments tied to development milestones. Gilead transaction size: $1.2 billion M&A - Nimbus’ ACC/NASH asset was licensed/sold to Gilead after phase 1b. Gilead upfront payment: $400 million - Initial payment in the ACC transaction. First milestone from Gilead deal: $200 million - Triggered within about six months of the upfront. Return to investors: ~10x on $63 million raised - Kazemi notes Nimbus had raised about $63 million prior to the Gilead deal. Program attrition: ~75% - Kazemi says Nimbus kills about three-quarters of its portfolio over time. Capital recycled through killing programs: Over $100 million - Money saved/recycled back into discovery by stopping programs early. TIC2 selectivity: 1.5 million-fold - He cites this as evidence of deep molecular understanding. Psoriasis response: About one-third reaching PASI 100 - Luke cites Takeda phase 3 results for the TIC2 asset. Comparator response: About 10-15% PASI 100 - Luke compares Takeda’s TIC2 data with Bristol-Myers Squibb’s first-mover program.

Pivotal Quotes: "We put the patient first." — Abbas Kazemi: Describing Nimbus culture and how employees are recruited and aligned. "Our platform is our people." — Abbas Kazemi: Explaining that Nimbus’ real advantage is talent, not proprietary infrastructure. "Can we kill more programs faster?" — Abbas Kazemi: His CEO vision for building a stronger compounding engine with faster decision-making.

Implications: Nimbus offers a model for lean biotech: use computation, strong target selection, and decisive portfolio pruning to create outsized value. For the industry, it shows that small teams can still produce blockbuster science if they stay disciplined and patient-centered.